Article
FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.
Oncotarget - 14 Feb 2017
Nguyen Bao, Williams Allen B, Young David J, Ma Hayley, Li Li, Levis Mark, Brown Patrick, Small Donald
Abstract excerpt
Fms-like tyrosine kinase-3 (FLT3) is a receptor tyrosine kinase that normally functions in hematopoietic cell survival, proliferation and differentiation. Constitutively activating mutations of FLT3 map predominately to the juxtamembrane domain (internal tandem duplications; ITD) or the activation loop (AL) of the kinase domain and are detected in about 1/3 of de novo acute myeloid leukemia (AML) patients. Small...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.